Dietary Adjuncts and Cardiovascular Disease Risk Reduction

Kevin Maki Dietary Adjuncts

Speaker Name / Credentials

Kevin C. Maki, PhD, CLS, FNLA, FTOS, FACN
Midwest Center for Metabolic & Cardiovascular Research, Chicago, Illinois

Estimated time of Talk

45 minutes

Description

This webinar will review the National Lipid Association recommendations for dietary modifications intended to lower levels of atherogenic cholesterol [low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C)], with an emphasis on dietary adjuncts to a diet low in saturated fats, trans fats, and cholesterol.

Learning Objectives

  • Review lipids and lipoproteins and their relationship to atherosclerotic cardiovascular disease (ASCVD) risk.
  • Discuss genetic variants associated with altered lipoprotein profiles and their relationships to ASCVD risk.
  • Discuss how dietary adjuncts, with or without pharmacological intervention, work to lower levels of LDL-C and non-HDL-C.
  • Review the effects of a combining a “portfolio” of dietary strategies on circulating levels of atherogenic cholesterol.

Disclosures

Dr. Maki is on the scientific advisory board or has consulted for AstraZeneca, Pharmavite, Matinas BioPharma, Sancilio & Co., National Dairy Council, Egg Nutrition Center, and National Cattlemen’s Beef Association and has received research grants from DuPont, AstraZeneca, AbbVie, ACH Foods, Matinas BioPharma, Shaklee, Egg Nutrition Center, National Dairy Council, National Cattlemen’s Beef Association and Sancilio & Co.

Familial Hypercholesterolemia (FH): Underdiagnosed and Undertreated

Seth Baum Familial Hypercholesterolemia

fh-foundation-logo

Speaker Name / Credentials

Seth J. Baum, MD, FACC, FAHA, FACPM, FNLA
Medical Director, Women’s Preventive Cardiology
Christine E. Lynn Women’s Health and Wellness Institute

Estimated time of Talk

45 minutes

Description

This webinar will review the pathophysiology of familial hypercholesterolemia (FH) as well as how to identify it and manage it using current and emerging therapies.

Learning Objectives

  • Review lipids and lipoproteins
  • Discuss FH as a genetic disorder
  • Discuss the pathophysiology of FH and how to screen and diagnose the disorder
  • Review the current management options and emerging therapies for FH

Disclosures

Dr. Baum is on the speaker’s bureau for Genzyme and a consultant for Aegerion, Kowa, and Solstas Lab Partners.